Annual report pursuant to Section 13 and 15(d)

Background and Organization (Details)

v3.24.0.1
Background and Organization (Details)
3 Months Ended 12 Months Ended
Sep. 19, 2022
USD ($)
$ / shares
shares
Sep. 30, 2023
USD ($)
$ / shares
shares
Dec. 31, 2023
USD ($)
segment
$ / shares
Dec. 31, 2022
USD ($)
$ / shares
Jul. 14, 2023
USD ($)
$ / shares
Dec. 21, 2021
$ / shares
shares
Dec. 16, 2020
$ / shares
Subsidiary, Sale of Stock [Line Items]              
Number of operating segments | segment     1        
Share price | $ / shares $ 0.50            
Net proceeds $ 4,490,605            
Warrants to purchase shares | shares 500,000         172,500  
Warrants exercise price | $ / shares $ 0.625         $ 12.50  
Warrants exercise price percentage of IPO Price 125.00%            
Net loss     $ 5,296,015 $ 12,247,834      
Net cash used in operating activities     4,870,489 11,467,797      
Accumulated deficit     $ 61,469,222 $ 56,173,207      
Common stock, par value (in dollars per share) | $ / shares     $ 0.0001 $ 0.0001     $ 0.0001
Proceeds from issuance of shares on ATM, net of fees $ 5,000,000   $ 1,156,443        
Substantial Doubt about Going Concern, within One Year [true false]     true        
Minimum              
Subsidiary, Sale of Stock [Line Items]              
Period in which the company has to raise additional capital to complete clinical development     6 months        
Maximum              
Subsidiary, Sale of Stock [Line Items]              
Period in which the company has to raise additional capital to complete clinical development     8 months        
IPO | Maximum              
Subsidiary, Sale of Stock [Line Items]              
Shares issued | shares 10,000,000            
Capital on Demand Sales Agreement [Member]              
Subsidiary, Sale of Stock [Line Items]              
Shares issued | shares   641,873          
Share price | $ / shares   $ 2.11          
Net proceeds   $ 1,156,440          
Offering costs   198,650          
Common stock, par value (in dollars per share) | $ / shares         $ 0.0001    
Aggregate offering price         $ 6,700,000    
Proceeds from issuance of shares on ATM, net of fees   $ 1,355,090